Understanding the GH Axis: Age-Related Decline and Peptide Research
Growth hormone declines by approximately 15% per decade after age 30. An overview of the biology and published preclinical research on GH secretagogue compounds.
The Somatotropic Axis
The growth hormone (GH) axis — also called the somatotropic axis — is a hormonal cascade involving the hypothalamus, pituitary gland, and liver. The hypothalamus releases Growth Hormone Releasing Hormone (GHRH), which stimulates the anterior pituitary to secrete GH in pulses. GH then acts on the liver to produce IGF-1 (Insulin-like Growth Factor 1), which mediates many of GH's anabolic and restorative effects throughout the body. Somatostatin, also from the hypothalamus, acts as the brake — inhibiting GH release to maintain homeostasis.
Somatopause: Age-Related GH Decline
GH production peaks during adolescence and begins declining from approximately age 25-30. The rate of decline is approximately 14-15% per decade. By age 60, most individuals produce less than half the GH they produced at age 25. This decline — termed somatopause — correlates with increased visceral adiposity, decreased lean muscle mass, reduced bone mineral density, thinning skin, impaired immune function, and decreased exercise capacity. Whether GH decline is a cause or consequence of aging remains an active area of research.
GHRH Analogues: CJC-1295
CJC-1295 is a synthetic 30-amino acid analogue of GHRH that stimulates the pituitary GHRH receptor. The no-DAC (no Drug Affinity Complex) variant has a half-life of approximately 30 minutes, producing acute GH pulses. The DAC variant extends the half-life to approximately 8 days by binding to serum albumin, producing more sustained GH elevation. Research has shown that CJC-1295 increases both GH and IGF-1 levels in a dose-dependent manner while preserving the pulsatile release pattern that is important for maintaining receptor sensitivity.
Ghrelin Mimetics: Ipamorelin
Ipamorelin is a selective pentapeptide agonist of the ghrelin receptor (GHSR-1a). It stimulates GH release through a different receptor pathway than GHRH — meaning it can be combined with CJC-1295 for additive effects. The key advantage of Ipamorelin over older ghrelin mimetics (GHRP-2, GHRP-6) is selectivity: it produces minimal elevation of cortisol, prolactin, or appetite — making it a cleaner research compound with fewer confounding variables in experimental models.
The CJC-1295 + Ipamorelin Combination
This is the most widely studied GH secretagogue combination in the research literature. The rationale is mechanistic synergy: CJC-1295 provides the GHRH signal (telling the pituitary to produce GH) while Ipamorelin provides the ghrelin signal (amplifying the release pulse). Together, they produce GH elevations greater than either compound alone. Research suggests this combination more closely mimics the physiological pattern of youthful GH secretion than either exogenous GH injection or single-agent secretagogue use.
Research Context and Limitations
While the mechanistic rationale for GH secretagogues is well-supported, it is important to note that most published research is in animal models or small human pharmacokinetic studies measuring hormone levels — not large-scale clinical trials measuring health outcomes. Whether restoring youthful GH levels through secretagogues produces the same benefits as naturally higher GH levels remains unproven. These compounds are not approved as medicines by the MHRA or any equivalent regulatory authority. All products are sold for in vitro research purposes only.
Research Disclaimer: All content on this page is provided for educational and informational purposes only. Information relates to research contexts and does not constitute medical advice. Silver Peptide products are sold for research purposes only and are not intended for human consumption.